title: 99mTc-sestaMIBI scintigraphy in thalidomide-treated refractory or relapsed multiple myeloma patients.
authors.forename: Claudia
authors.initials: C
authors.lastname: Andretta
authors.forename: Lucio
authors.initials: L
authors.lastname: Catalano
authors.forename: Leonardo
authors.initials: L
authors.lastname: Pace
authors.forename: Rosa
authors.initials: R
authors.lastname: Fonti
authors.forename: Gaetana
authors.initials: G
authors.lastname: Annunziata
authors.forename: Bruno
authors.initials: B
authors.lastname: Rotoli
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001853:Bone Marrow / Q000000981:diagnostic imaging; D003907:Dexamethasone / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008558:Melphalan / Q000627:therapeutic use; D008875:Middle Aged; D009101:Multiple Myeloma / Q000000981:diagnostic imaging* / Q000188:drug therapy*; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D017256:Technetium Tc 99m Sestamibi / Q000493:pharmacokinetics; D013792:Thalidomide / Q000627:therapeutic use*; D014018:Tissue Distribution
chemical_list: D000970:Antineoplastic Agents; D019275:Radiopharmaceuticals; D013792:Thalidomide; D003907:Dexamethasone; D017256:Technetium Tc 99m Sestamibi; D008558:Melphalan